Legend: AMD -age related macular degeneration; CTL -control; ERL -early AMD; INT -intermediate AMD; LAT -late AMD. For each box plot, yellow dots represent the mean and black horizontal lines represent the median. In addition to the AMD/Control model (i.e. multivariable logistic regression model considering AMD vs controls as the outcome) and the Stage+2 Eye (i.e. permutation-based cumulative logistic regression model considering both eyes of each patient and using severity stage of disease as the outcome (control, early, intermediate and late)), we present an additional model (cumulative logistic regression model) also having as the outcome stages of disease (control, early, intermediate and late) but per individual and not accounting for each eye separately. For this model (similarly to the AMD/Control model) if the two eyes of each individual presented a different AMD stage the worst was considered. The list of metabolites differing significantly between AMD and controls based on q-value is presented on metabolite set A+B+C. Considering the Stage model, these can be divided into two groups (i.e. set A vs. set B+C) that contain metabolites with the significantly different adjusted intensity between AMD vs. controls but with no significant linear trends across stages (set A), or with significant linear patterns across stages (set B+C). The list of identified metabolites based on q-value using all stages of AMD is presented above (set B+D). Only one metabolite (i.e. alpha-tocopherol) was additionally detected using the Stage model . Using AMD stages of both eyes, we identified an additional set of metabolites (set E) that had similar levels between AMD vs. controls but significant linear trends within AMD stages. The full lists of the significant metabolites for both cohort analyses and meta-analyses are presented in Supplementary Tables 14-16 ) the baseline model with demographic covariates alone (red). All three models performed better than All-Met+EN model (i.e. elastic net with all metabolites, orange), which performed better (p=2.87×10 ) than the baseline model with demographic covariates alone (red). The Stage model performed better than AMD/Control model, as it used AMD stages, but worse than Stage+2Eye, as it used only AMD stages of each subject rather than information on each eye. Also, all three models performed better than All-Met+EN model (orange), which outperformed (p=2.27×10 -4 ) the baseline model (red). AUC were also computed using combined meta-analysis results. Stage+2Eye model (i.e. disease stages of both eyes; dark blue), Stage model (disease stages of severe eye; light blue) and AMD/Control model (i.e. AMD vs controls; green) outperformed (p=3.74*10 -6 , p=1.65*10 -4 , p=2.07*10 -4 ) the baseline model (red). And all three models performed better than All-Met+EN model (orange), which performed similarly (p=1.36×10 -1 ) to the baseline model (red) (see Supplementary Table 17 for more details).
Supplementary Figure 5. Proportional odds assumption for the two cohort data (Boston, US
and Coimbra, Portugal). For each predictor variable (including 4 clinical covariates and 544 metabolites), distance between the symbols for each set of categories of the dependent variable remains similar and thus the proportional odds assumption holds.
To evaluate suitability of the model, we checked the proportional odds assumption for each covariate and found that estimated difference in log-odds of AMD stage for each set of categories of AMD stages were similar for each metabolite or clinical covariate, which indicated the cumulative logistic model fits our data. Legend: OR -Odds Ratio; Pval -P-value; Qval -q-value; US -United States; Qval_Sig -indicator for significance based on q-value. Legend: OR -Odds Ratio; Pval -P-value; Qval -q-value; PT-Portugal; US -United States; Meta -Meta analysis; Qval_Sig -indicator for significance based on q-value. Figure 2 and their p-values from AMD/Control and Stage+2Eye models from Boston cohort. Supplementary Table 9 . List of the metabolites in Figure 2 and their p-values from AMD/Control and Stage+2Eye models from Portuguese cohort. Figure 2 and their p-values from AMD/Control and Stage+2Eye models from the meta analysis. 
Supplementary Table 1. Metabolites differing significantly between patients with AMD and controls, using Boston (US) samples based on p-values of AMD/Control model.

Supplementary
Black 0 (0) 0 (0) 4 (2) 2 (3) Asian 0 (0) 0 (0) 0 (0) 0 (0) Hispanic 0 (0) 0 (0) 0 (0) 0 (0) SupplementaryLysophospholipid 1-oleoyl-GPE (18:1) 1.26 4.56E-03 7.96E-02 0 Lipid Monoacylglycerol 2-oleoylglycerol (18:1) 0.80 4.68E-03 7.96E-02 0 Lipid Fatty Acid Metabolism(Acyl Carnitine) dihomo-linolenoylcarnitine (C20:3n3 or 6)* 1.26 5.07E-03 8.36E-02 0
Supplementary Table 8. List of the metabolites in
